The impact of a pharmacist-led educational interview on medication adherence of Saudi patients with epilepsy

Figures & data

Table 1 Demographics and clinical characteristics of the study population

Characteristic	Control group N (%)	Intervention group N (%)
Gender
Male	16 (55.2)	14 (51.9)
Female	13 (44.8)	13 (48.1)
Age (years)
20–30	12 (41.4)	15 (55.6)
31–40	12 (41.4)	6 (22.2)
41–50	3 (10.3)	5 (18.5)
51–60	2 (6.9)	1 (3.7)
Marital status
Single	14 (48.3)	15 (55.6)
Married	14 (48.3)	12 (44.4)
Widowed	1 (3.4)	0 (0)
Education level
Primary	7 (24.1)	4 (143.8)
Intermediate	5 (17.2)	3 (11.1)
High school	10 (34.5)	12 (44.4)
University	7 (24.1)	8 (29.6)
Live with family
Yes	24 (82.8)	21 (77.8)
No	5 (17.2)	6 (22.2)
Occupational status
Working	11 (37.9)	9 (33.3)
Not working	18 (62.1)	18 (66.7)
Duration of illness (years)
<10	9 (31)	11 (40.7)
≥10	20 (69)	16 (59.3)
Seizure frequency
Daily	7 (24.1)	5 (18.5)
Last seizure was within a month	13 (44.8)	7 (25.9)
Last seizure was within 3 months	6 (20.7)	5 (18.5)
Number of AEDs
1	6 (20.7)	8 (29.6)
>1	23 (79.3)	19 (70.4)
Type of AEDs
Carbamazepine	16 (55.2)	17 (63.0)
Levetiracetam	18 (62.1)	14 (51.9)
Lamotrigine	10 (34.5)	8 (29.6)
Topiramate	14 (48.3)	7 (25.9)
Valproic acid	7 (24.1)	8 (29.6)
Phenytoin	3 (10.3)	1 (3.7)

Abbreviation: AEDs, antiepileptic drugs.

Table 2 Comparison of adherence level between control (N=29) and intervention (N=27) groups

Adherence level (points)	Baseline, n (%)		P-value	6 weeks after intervention, n (%)		P-value
	Control group	Intervention group		Control group	Intervention group
High (8)	7 (24.1)	0 (0)	0.007**	4 (13.8)	3 (11.1)	0.541**
Medium (6–8)	11 (37.9)	11 (40.7)	0.830*	14 (48.3)	23 (85.2)	0.004*
Low (<6)	11 (37.9)	16 (59.3)	0.110*	11 (37.9)	1 (3.7)	0.002*

Notes:

* By Chi-square test;

** by Fisher’s exact test.